explore -WSS

explore

author：hotspot 2025-09-10 08:44:20 - browse：616

Beam Therapeutics said Thursday morning it would lay off 20% of its staff — or around 100 employees — and pause or reevaluate certain programs as it looks to cut costs.

It’s a notable setback for a gene-editing company that quickly raised over $1 billion in the few years after its co-founder, David Liu, described a new form of CRISPR, called base editing, that allowed researchers to change individual letters of DNA. The biotech hired rapidly, announced its intention to treat a broad range of diseases, and received clearance to start clinical trials in cancer and sickle cell.

Beam, however, has struggled to enroll patients in those trials. Meanwhile, the biotech stock market has stayed cold, including for gene-editing companies, whose technologies raise new regulatory, safety, and reimbursement questions. The pending approval of two gene therapies for sickle cell would also limit the market for Beam’s lead drug.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medical records are filled with copy
Next article： Newly revealed memo details efforts to keep Trump in power following election loss

focus

hotspot

WSS

How state and local governments are sidelining science

Maui funeral service workers on devastation of fires: 'I'm in shock'

Newly revealed memo details efforts to keep Trump in power following election loss

Today's health inequities arise from racist U.S. history, say experts

Timeline: Special counsel's investigation into Trump's handling of classified documents

After John Oliver segment, STAT readers share their opioid

leisure time

explore

explore

In age of alternative facts, a scholarly course on calling out crap

Type 2 diabetes prevention programs work at large scale: study

How one medical school became remarkably diverse

White House drug czar issues call for 'recovery

New air purifier tech could be key to improving indoor air quality

NIH chief: government has fallen behind pharma on clinical trials

What does generative AI mean for health care? We asked experts

House GOP releases memo on Hunter Biden foreign business dealings, reviving old claims

Trump demands the U.S. pay no more for drugs than other countries … again

NIH chief: government has fallen behind pharma on clinical trials

hotspot

Readout Newsletter: Zepbound, Valneva's vaccine, and more

Some of the ways extreme heat will change life as we know it

FDA cancer chief on how to get things done: ‘Don’t tell anybody'

Covid's long

House GOP releases memo on Hunter Biden foreign business dealings, reviving old claims

Iran moves toward freeing 5 American citizens who had been imprisoned, in rare deal

knowledge

focus

hotspot

leisure time